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early distal tubule fluid is not K secretion at the early DCT,
but rather a reduction in K reabsorption in the TAL.
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To the Editor: The recent in vitro studies of the Slatopolsky
group1 have shown that the ‘non active’ 25-OH-vitamin D
metabolite was actually efficient (even though less potent) at
physiological concentration for suppressing parathyroid
hormone synthesis by direct stimulation of the vitamin D
receptor, and that this direct stimulation was even pre-
ponderant over that induced by 1,25(OH) vitamin D3
produced in situ. This is consistent with our earlier reports
evidencing (1) in predialysis patients,2 a good long-term
control of hyperparathyroid bone disease by just normocal-
cemic dose of 25-OH-vitamin D in association with up to
2.4 g/day of CaCO3 and (2) in dialysis patients,
3 an
independent inverse link between parathyroid hormone and
25-OH-vitamin D serum concentrations independently of
serum concentrations of calcitriol, calcium, and phosphate.
This challenges the NKF-K/DOQI recommendation for
suppressing intact parathyroid hormone 4300 pg/ml in
dialysis patients, to inject hypercalcemic and hyperpho-
sphatemic dose of calcitriol and paricalcitol, instead of
correcting the highly prevalent (87%) vitamin D deficiency in
American patients. This correction would decrease the need
of ‘active’ vitamin D derivatives for this suppression, while
better preventing vascular calcification (in spite of concomi-
tant use of calcium–phosphate binder) as suggested by the
comparison of the two cohorts of young adults with
childhood-onset of end-stage renal disease, as quoted in
our letter to Kidney International about Kalantar-Zadeh
article,4 pointing out that the survival benefit granted by
paricalcitol was inversely related to its dose.
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The letter from Shahapuni et al.1 cites our finding that
25-hydroxyvitamin D3 (25(OH)D3) suppresses parathyroid
hormone (PTH) synthesis in cultured parathyroid cells2 to
emphasize earlier studies from their group (1) demonstrat-
ing the skeletal benefits of improving vitamin D status in
chronic kidney disease patients, and (2) the inverse
correlation of PTH with 25(OH)D3 but not with calcitriol
in dialysis patients, relationships that have also been
documented in the general population.3
In response, we feel it necessary to clarify two points in
the letter. First, the authors incorrectly state that our data
showed that 25(OH)D3 produced a greater decrease in PTH
than calcitriol. In fact, the maximal reduction in both PTH
secretion and PTH mRNA was not different. Second, the K/
DOQI guidelines do not recommend injecting hypercalce-
mic or hyperphosphatemic doses of calcitriol or its analogs
as stated in the letter. The algorithms clearly state the
target ranges for plasma Ca and P and suggest modifica-
tions when they are exceeded.
The K/DOQI guidelines recommend ergocalciferol
supplementation in predialysis patients with 25(OH)D3
levels less than 30 ng/ ml, but as Shahapuni et al. point out,
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